Search

Your search keyword '"Heijmans, Jarom"' showing total 327 results
Start Over Author "Heijmans, Jarom"
327 results on '"Heijmans, Jarom"'

3. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Author

Kant, Iris M.J., Graas, Thecla, Toussaint, Belle, de Jong, Sterre, Darwesh, Shahan, Mahes, Sandjiv S., Kamminga, Dora, Koelewijn, Matthijs, Faber, Gino, Beaumont, Guus, Engel, Marije D., Pierie, R. Cheyenne N., Janssen, Suzanne R., van Dijkman, Edith, Heijmans, Jarom, Witte, Yara Y., Nahui Palomino, Rogers A., Omar, Said Z., Zweegman, Sonja, Kater, Arnon P., van den Vegt, Caya, Arends-Halbesma, Ilonka, de Pater, Emma, Dijkstra, Margriet J., Rots, Nynke Y., Rijnstra, Esther Siteur-van, de Rooij, Dennis M., Sanders, Rogier W., Poniman, Meliawati, Olijhoek, Wouter, van Rijswijk, Jacqueline, Beaumont, Tim, Çetinel, Lusia, Schellekens, Louis, den Hartogh, Yvonne M., Cloos, Jacqueline, Weijers, Suzanne S., Tonouh-Aajoud, Saïda, Avci, Selime, Roelandse-Koop, Elianne, Dik, Willem A., Hofsink, Quincy, Haggenburg, Sabine, Lissenberg-Witte, Birgit I., Broers, Annoek E.C., van Doesum, Jaap A., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., van Meerloo, Johan, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby P., Wouters, Dorine, van Leeuwen, Ester M.M., Bontkes, Hetty J., Kootstra, Neeltje A., Vogels-Nooijen, Sandra, Rots, Nynke, van Beek, Josine, Heemskerk, Mirjam H.M., Groen, Kazimierz, van Meerten, Tom, Mutsaers, Pim G.N.J., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Published
2023
Full Text
View/download PDF

12. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response

Author

Grootjans, Joep, Krupka, Niklas, Hosomi, Shuhei, Matute, Juan D., Hanley, Thomas, Saveljeva, Svetlana, Gensollen, Thomas, Heijmans, Jarom, Li, Hai, Limenitakis, Julien P., Ganal-Vonarburg, Stephanie C., Suo, Shengbao, Luoma, Adrienne M., Shimodaira, Yosuke, Duan, Jinzhi, Shih, David Q., Conner, Margaret E., Glickman, Jonathan N., Fuhler, Gwenny M., Palm, Noah W., de Zoete, Marcel R., van der Woude, C. Janneke, Yuan, Guo-Cheng, Wucherpfennig, Kai W., Targan, Stephan R., Rosenstiel, Philip, Flavell, Richard A., McCoy, Kathy D., Macpherson, Andrew J., Kaser, Arthur, and Blumberg, Richard S.

Published
2019

14. ATF2 and ATF7 Are Critical Mediators of Intestinal Epithelial Repair

Author

Meijer, Bartolomeus J., Giugliano, Francesca P., Baan, Bart, van der Meer, Jonathan H.M., Meisner, Sander, van Roest, Manon, Koelink, Pim J., de Boer, Ruben J., Jones, Nic, Breitwieser, Wolfgang, van der Wel, Nicole N., Wildenberg, Manon E., van den Brink, Gijs R., Heijmans, Jarom, and Muncan, Vanesa

Published
2020
Full Text
View/download PDF

16. Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis

Author

van der Meer, Jonathan H. M., de Boer, Ruben J., Meijer, Bartolomeus J., Smit, Wouter L., Vermeulen, Jacqueline L. M., Meisner, Sander, van Roest, Manon, Koelink, Pim J., Dekker, Evelien, Hakvoort, Theodorus B. M., Koster, Jan, Hawinkels, Lukas J. A. C., Heijmans, Jarom, Struijs, Eduard A., Boermeester, Marja A., van den Brink, Gijs R., and Muncan, Vanesa

Published
2021
Full Text
View/download PDF

18. Blimp1 regulates the transition of neonatal to adult intestinal epithelium.

Author

Muncan, Vanesa, Heijmans, Jarom, Krasinski, Stephen D, Büller, Nikè V, Wildenberg, Manon E, Meisner, Sander, Radonjic, Marijana, Stapleton, Kelly A, Lamers, Wout H, Biemond, Izak, van den Bergh Weerman, Marius A, O'Carroll, Dónal, Hardwick, James C, Hommes, Daniel W, and van den Brink, Gijs R

Subjects
Intestinal Mucosa, Animals, Mice, Transgenic, Mice, Knockout, Mice, Transcription Factors, Gene Expression Regulation, Developmental, Female, Male, Positive Regulatory Domain I-Binding Factor 1, Gene Expression Regulation, Developmental, Knockout, Transgenic
Abstract

In many mammalian species, the intestinal epithelium undergoes major changes that allow a dietary transition from mother's milk to the adult diet at the end of the suckling period. These complex developmental changes are the result of a genetic programme intrinsic to the gut tube, but its regulators have not been identified. Here we show that transcriptional repressor B lymphocyte-induced maturation protein 1 (Blimp1) is highly expressed in the developing and postnatal intestinal epithelium until the suckling to weaning transition. Intestine-specific deletion of Blimp1 results in growth retardation and excessive neonatal mortality. Mutant mice lack all of the typical epithelial features of the suckling period and are born with features of an adult-like intestine. We conclude that the suckling to weaning transition is regulated by a single transcriptional repressor that delays epithelial maturation.

Published
2011

19. Intestinal tumorigenesis is not affected by progesterone signaling in rodent models.

Author

Heijmans, Jarom, Muncan, Vanesa, Jacobs, Rutger J, de Jonge-Muller, Eveline SM, Graven, Laura, Biemond, Izak, Ederveen, Antwan G, Groothuis, Patrick G, Mosselman, Sietse, Hardwick, James C, Hommes, Daniel W, and van den Brink, Gijs R

Subjects
Intestinal Mucosa, Colon, Intestine, Small, Animals, Mice, Rats, Intestinal Neoplasms, Cell Transformation, Neoplastic, Intestinal Polyposis, Disease Models, Animal, Progesterone, Receptors, Progesterone, Progestins, Immunohistochemistry, Signal Transduction, Cell Proliferation, Cell Transformation, Neoplastic, Disease Models, Animal, Intestine, Small, Receptors, General Science & Technology
Abstract

Clinical data suggest that progestins have chemopreventive properties in the development of colorectal cancer. We set out to examine a potential protective effect of progestins and progesterone signaling on colon cancer development. In normal and neoplastic intestinal tissue, we found that the progesterone receptor (PR) is not expressed. Expression was confined to sporadic mesenchymal cells. To analyze the influence of systemic progesterone receptor signaling, we crossed mice that lacked the progesterone receptor (PRKO) to the Apc(Min/+) mouse, a model for spontaneous intestinal polyposis. PRKO-Apc(Min/+) mice exhibited no change in polyp number, size or localization compared to Apc(Min/+). To examine effects of progestins on the intestinal epithelium that are independent of the PR, we treated mice with MPA. We found no effects of either progesterone or MPA on gross intestinal morphology or epithelial proliferation. Also, in rats treated with MPA, injection with the carcinogen azoxymethane did not result in a difference in the number or size of aberrant crypt foci, a surrogate end-point for adenoma development. We conclude that expression of the progesterone receptor is limited to cells in the intestinal mesenchyme. We did not observe any effect of progesterone receptor signaling or of progestin treatment in rodent models of intestinal tumorigenesis.

Published
2011

20. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.

Author

Kodach, Liudmila L, Jacobs, Rutger J, Heijmans, Jarom, van Noesel, Carel JM, Langers, Alexandra MJ, Verspaget, Hein W, Hommes, Daniel W, Offerhaus, G Johan A, van den Brink, Gijs R, and Hardwick, James CH

Subjects
Humans, Colorectal Neoplasms, DNA-Binding Proteins, Transcription Factors, RNA, Messenger, Blotting, Western, Immunoenzyme Techniques, Enzyme-Linked Immunosorbent Assay, Electrophoretic Mobility Shift Assay, Tissue Array Analysis, Chromatin Immunoprecipitation, Reverse Transcriptase Polymerase Chain Reaction, DNA Methylation, Gene Expression Regulation, Neoplastic, Gene Silencing, Regulatory Sequences, Nucleic Acid, Genes, Tumor Suppressor, Core Binding Factor Alpha 3 Subunit, Promoter Regions, Genetic, Enhancer of Zeste Homolog 2 Protein, Polycomb Repressive Complex 2, Blotting, Western, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Promoter Regions, Genetic, RNA, Messenger, Regulatory Sequences, Nucleic Acid, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

In gastric cancer, a new epigenetic mechanism of tumour suppressor loss has been suggested where the histone methyltransferase enhancer of zeste homolog 2 (EZH2) is responsible for loss of expression of RUNX3. This is consistent with EZH2 upregulation in multiple cancer types being associated with poor prognosis. We investigated whether EZH2 influences the expression of RUNX3 in colorectal cancer (CRC) and whether this is independent of methylation. We determined protein and messenger RNA (mRNA) levels of EZH2 and RUNX3 and assessed RUNX3 methylation with methylation-specific polymerase chain reaction using 72 human CRCs and 8 CRC cell lines. We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation. Despite higher levels of EZH2 and lower levels of RUNX3 in CRC specimens in general, no inverse correlation between EZH2 and RUNX3 in paired samples was found arguing against a major role for histone methylation in silencing RUNX3 in CRC. Conversely, downregulation of RUNX3 mRNA in the same tumours was associated with RUNX3 DNA methylation (P < 0.05). In cell lines, knockdown of EZH2 removed the repressive chromatin marks from RUNX3 but did not result in RUNX3 re-expression. However, it prevented the re-silencing of RUNX3 after the removal of demethylating agents. In conclusion, DNA methylation is primarily responsible for the transcriptional silencing of RUNX3 in CRC, but EZH2 and histone methylation are necessary for its methylation-dependent re-silencing after the removal of demethylating agents. These results would predict that inhibitors of EZH2 and histone methylation would enhance the effects of demethylating agents in cancer therapy.

Published
2010

21. Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis

Author

Spaan, Claudia N, primary, de Boer, Ruben J, additional, Smit, Wouter L, additional, van der Meer, Jonathan HM, additional, van Roest, Manon, additional, Vermeulen, Jacqueline LM, additional, Koelink, Pim J, additional, Becker, Marte AJ, additional, Go, Simei, additional, Silva, Joana, additional, Faller, William J, additional, van den Brink, Gijs R, additional, Muncan, Vanesa, additional, and Heijmans, Jarom, additional

Published
2023
Full Text
View/download PDF

23. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019

Author

Huygens, Sammy, Hofsink, Quincy, Nijhof, Inger S., Goorhuis, Abraham, Kater, Arnon P., Te Boekhorst, Peter A.W., Swaneveld, Francis, Novotný, Věra M.J., Bogers, Susanne, Welkers, Matthijs R.A., Papageorgiou, Grigorios, Rijnders, Bart J., Heijmans, Jarom, Graduate School, Clinical Haematology, Infectious diseases, APH - Aging & Later Life, APH - Global Health, AII - Infectious diseases, Experimental Immunology, AII - Cancer immunology, CCA - Cancer biology and immunology, Medical Microbiology and Infection Prevention, General Internal Medicine, Internal Medicine, Hematology, Virology, and Epidemiology

Subjects
Infectious Diseases, SDG 3 - Good Health and Well-being, Immunology and Allergy, COVID-19, plasma-derived antibody therapy, anti-SARS-CoV-2 hyperimmune globulin, severely immunocompromised state, B-cell dysfunction
Abstract

Background The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Methods Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher’s exact test). Conclusions Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

Published
2023
Full Text
View/download PDF

24. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Author

Hofsink, Quincy, primary, Haggenburg, Sabine, additional, Lissenberg-Witte, Birgit I., additional, Broers, Annoek E.C., additional, van Doesum, Jaap A., additional, van Binnendijk, Rob S., additional, den Hartog, Gerco, additional, Bhoekhan, Michel S., additional, Haverkate, Nienke J.E., additional, van Meerloo, Johan, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Smits, Gaby P., additional, Wouters, Dorine, additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Vogels-Nooijen, Sandra, additional, Rots, Nynke, additional, van Beek, Josine, additional, Heemskerk, Mirjam H.M., additional, Groen, Kazimierz, additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, van Gils, Marit J., additional, Goorhuis, Abraham, additional, Rutten, Caroline E., additional, Hazenberg, Mette D., additional, Nijhof, Inger S., additional, Kant, Iris M.J., additional, Graas, Thecla, additional, Toussaint, Belle, additional, de Jong, Sterre, additional, Darwesh, Shahan, additional, Mahes, Sandjiv S., additional, Kamminga, Dora, additional, Koelewijn, Matthijs, additional, Faber, Gino, additional, Beaumont, Guus, additional, Engel, Marije D., additional, Pierie, R. Cheyenne N., additional, Janssen, Suzanne R., additional, van Dijkman, Edith, additional, Heijmans, Jarom, additional, Witte, Yara Y., additional, Nahui Palomino, Rogers A., additional, Omar, Said Z., additional, Zweegman, Sonja, additional, Kater, Arnon P., additional, van den Vegt, Caya, additional, Arends-Halbesma, Ilonka, additional, de Pater, Emma, additional, Dijkstra, Margriet J., additional, Rots, Nynke Y., additional, Rijnstra, Esther Siteur-van, additional, de Rooij, Dennis M., additional, Sanders, Rogier W., additional, Poniman, Meliawati, additional, Olijhoek, Wouter, additional, van Rijswijk, Jacqueline, additional, Beaumont, Tim, additional, Çetinel, Lusia, additional, Schellekens, Louis, additional, den Hartogh, Yvonne M., additional, Cloos, Jacqueline, additional, Weijers, Suzanne S., additional, Tonouh-Aajoud, Saïda, additional, Avci, Selime, additional, Roelandse-Koop, Elianne, additional, and Dik, Willem A., additional

Published
2023
Full Text
View/download PDF

26. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019:A Randomized, Controlled Trial

Author

Huygens, Sammy, Hofsink, Quincy, Nijhof, Inger S., Goorhuis, Abraham, Kater, Arnon P., Te Boekhorst, Peter A.W., Swaneveld, Francis, Novotný, Věra M.J., Bogers, Susanne, Welkers, Matthijs R.A., Papageorgiou, Grigorios, Rijnders, Bart J., Heijmans, Jarom, Huygens, Sammy, Hofsink, Quincy, Nijhof, Inger S., Goorhuis, Abraham, Kater, Arnon P., Te Boekhorst, Peter A.W., Swaneveld, Francis, Novotný, Věra M.J., Bogers, Susanne, Welkers, Matthijs R.A., Papageorgiou, Grigorios, Rijnders, Bart J., and Heijmans, Jarom

Abstract

BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

Published
2023

27. Supplementary Figure legends from Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation

Author

van Lidth de Jeude, Jooske F., primary, Spaan, Claudia N., primary, Meijer, Bartolomeus J., primary, Smit, Wouter L., primary, Soeratram, Tanya T.D., primary, Wielenga, Mattheus C.B., primary, Westendorp, B. Florien, primary, Lee, Amy S., primary, Meisner, Sander, primary, Vermeulen, Jacqueline L.M., primary, Wildenberg, Manon E., primary, van den Brink, Gijs R., primary, Muncan, Vanesa, primary, and Heijmans, Jarom, primary

Published
2023
Full Text
View/download PDF

28. Figure S2 from Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation

Author

van Lidth de Jeude, Jooske F., primary, Spaan, Claudia N., primary, Meijer, Bartolomeus J., primary, Smit, Wouter L., primary, Soeratram, Tanya T.D., primary, Wielenga, Mattheus C.B., primary, Westendorp, B. Florien, primary, Lee, Amy S., primary, Meisner, Sander, primary, Vermeulen, Jacqueline L.M., primary, Wildenberg, Manon E., primary, van den Brink, Gijs R., primary, Muncan, Vanesa, primary, and Heijmans, Jarom, primary

Published
2023
Full Text
View/download PDF

29. Data from Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation

Author

van Lidth de Jeude, Jooske F., primary, Spaan, Claudia N., primary, Meijer, Bartolomeus J., primary, Smit, Wouter L., primary, Soeratram, Tanya T.D., primary, Wielenga, Mattheus C.B., primary, Westendorp, B. Florien, primary, Lee, Amy S., primary, Meisner, Sander, primary, Vermeulen, Jacqueline L.M., primary, Wildenberg, Manon E., primary, van den Brink, Gijs R., primary, Muncan, Vanesa, primary, and Heijmans, Jarom, primary

Published
2023
Full Text
View/download PDF

30. Stromal Indian Hedgehog Signaling Is Required for Intestinal Adenoma Formation in Mice

Author

Büller, Nikè V.J.A., Rosekrans, Sanne L., Metcalfe, Ciara, Heijmans, Jarom, van Dop, Willemijn A., Fessler, Evelyn, Jansen, Marnix, Ahn, Christina, Vermeulen, Jacqueline L.M., Westendorp, B. Florien, Robanus-Maandag, Els C., Offerhaus, G. Johan, Medema, Jan Paul, D’Haens, Geert R.A.M., Wildenberg, Manon E., de Sauvage, Frederic J., Muncan, Vanesa, and van den Brink, Gijs R.

Published
2015
Full Text
View/download PDF

31. Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Author

Tang, Man Wai, primary, van der Tuin, Deborah, additional, Aydin, Mesire, additional, Heijmans, Jarom, additional, van de Loosdrecht, Arjan A., additional, Meijer, Ellen, additional, Rutten, Caroline E., additional, Wondergem, Marielle, additional, Janssen, Jeroen J.W.M., additional, Donker, Marjolein, additional, Hazenberg, Mette D., additional, Zweegman, Sonja, additional, Biemond, Bart J., additional, de Leeuw, David C., additional, and Nur, Erfan, additional

Published
2022
Full Text
View/download PDF

34. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

Author

Huygens, Sammy, primary, Hofsink, Quincy, additional, Nijhof, Inger S, additional, Goorhuis, Abraham, additional, Kater, Arnon P, additional, te Boekhorst, Peter A W, additional, Swaneveld, Francis, additional, Novotný, Věra M J, additional, Bogers, Susanne, additional, Welkers, Matthijs R A, additional, Papageorgiou, Grigorios, additional, Rijnders, Bart J, additional, and Heijmans, Jarom, additional

Published
2022
Full Text
View/download PDF

35. ER Stress Causes Rapid Loss of Intestinal Epithelial Stemness through Activation of the Unfolded Protein Response

Author

Heijmans, Jarom, van Lidth de Jeude, Jooske F., Koo, Bon-Kyoung, Rosekrans, Sanne L., Wielenga, Mattheus C.B., van de Wetering, Marc, Ferrante, Marc, Lee, Amy S., Onderwater, Jos J.M., Paton, James C., Paton, Adrienne W., Mommaas, A. Mieke, Kodach, Liudmila L., Hardwick, James C., Hommes, Daniël W., Clevers, Hans, Muncan, Vanesa, and van den Brink, Gijs R.

Published
2013
Full Text
View/download PDF

36. Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties

Author

Schwitalla, Sarah, Fingerle, Alexander A., Cammareri, Patrizia, Nebelsiek, Tim, Göktuna, Serkan I., Ziegler, Paul K., Canli, Ozge, Heijmans, Jarom, Huels, David J., Moreaux, Guenievre, Rupec, Rudolf A., Gerhard, Markus, Schmid, Roland, Barker, Nick, Clevers, Hans, Lang, Roland, Neumann, Jens, Kirchner, Thomas, Taketo, Makoto M., van den Brink, Gijs R., Sansom, Owen J., Arkan, Melek C., and Greten, Florian R.

Published
2013
Full Text
View/download PDF

37. Inactivation of Patched1 in Mice Leads to Development of Gastrointestinal Stromal-Like Tumors That Express Pdgfrα but Not Kit

Author

Pelczar, Penelope, Zibat, Arne, van Dop, Willemijn A., Heijmans, Jarom, Bleckmann, Annalen, Gruber, Wolfgang, Nitzki, Frauke, Uhmann, Anja, Guijarro, Maria V., Hernando, Eva, Dittmann, Kai, Wienands, Jürgen, Dressel, Ralf, Wojnowski, Leszek, Binder, Claudia, Taguchi, Takahiro, Beissbarth, Tim, Hogendoorn, Pancras C.W., Antonescu, Cristina R., Rubin, Brian P., Schulz–Schaeffer, Walter, Aberger, Fritz, van den Brink, Gijs R., and Hahn, Heidi

Published
2013
Full Text
View/download PDF

38. Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study

Author

de la Court, Jara R, Woudt, Sjoukje H S, Schoffelen, Annelot F, Heijmans, Jarom, de Jonge, Nick A, van der Bruggen, Tjomme, Bomers, Marije K, Lambregts, Merel M C, Schade, Rogier P, and Sigaloff, Kim C E

Subjects
Third-generation-cephalosporin resistance, Febrile neutropenia, Colonization, Resistance surveillance, Antimicrobial resistance, Empirical antibiotic therapy
Abstract

Objectives Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative pathogens to third-generation cephalosporins is increasing. We aimed to assess the distribution of pathogens causing bacteraemia in patients with haematological malignancy, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization. Methods Using 11 years of data (2008–2018) from the Dutch national antimicrobial resistance surveillance system, we assessed the prevalence of third-generation cephalosporin resistant Gram-negative bacteria (3GC-R GNB) in episodes of bacteraemia, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization (identified using surveillance cultures) in the year before. Results We included 3,887 patients, representing 4,142 episodes of bacteraemia. GNB were identified in 715/4,142 (17.3%), of which 221 (30.9%) were 3GC-R GNB. In (106/139) 76.2% of patients with a 3GC-R GNB bacteraemia and available GNB surveillance cultures in the preceding year, 3GC-R GNB colonization had been previously identified. Conclusions This multi-centre study shows that in patients with haematological malignancy, the majority of 3GC-R GNB bacteraemia is preceded by 3GC-R GNB colonization. Prospective clinical studies are needed to assess the safety and benefits of surveillance-culture guided empirical therapy to restrict the empirical use of carbapenems in this population.

Published
2022
Full Text
View/download PDF

39. Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; the value of a surveillance-culture-guided empirical therapy approach

Author

Court, Jara R. de la, primary, Woudt, Sjoukje H. S., additional, Schoffelen, Annelot F., additional, Heijmans, Jarom, additional, de Jonge, Nick A., additional, Bruggen, Tjomme van der, additional, Bomers, Marije K., additional, Lambregts, Merel M. C., additional, Schade, Rogier P., additional, and Sigaloff, Kim C.E., additional

Published
2022
Full Text
View/download PDF

40. Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study

Author

Court, Jara R. de la, primary, Woudt, Sjoukje H. S., additional, Schoffelen, Annelot F., additional, Heijmans, Jarom, additional, de Jonge, Nick A., additional, Bruggen, Tjomme van der, additional, Bomers, Marije K., additional, Lambregts, Merel M. C., additional, Schade, Rogier P., additional, and Sigaloff, Kim C.E., additional

Published
2022
Full Text
View/download PDF

42. Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study

Author

MMB Medische Staf, Infection & Immunity, de la Court, Jara R, Heijmans, Jarom, Huynh, Jennifer, Sieswerda, Elske, de Jonge, Nick A, van Dijk, Karin, Sigaloff, Kim C E, Schade, Rogier P, MMB Medische Staf, Infection & Immunity, de la Court, Jara R, Heijmans, Jarom, Huynh, Jennifer, Sieswerda, Elske, de Jonge, Nick A, van Dijk, Karin, Sigaloff, Kim C E, and Schade, Rogier P

Published
2022

43. SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial

Author

Huygens, Sammy, primary, Hofsink, Quincy, additional, Nijhof, Inger S, additional, Goorhuis, Abraham, additional, Kater, Arnon P, additional, te Boekhorst, Peter AW, additional, Swaneveld, Francis, additional, Novotný, Věra MJ, additional, Bogers, Susanne, additional, Welkers, Matthijs RA, additional, Papageorgiou, Grigorios, additional, Rijnders, Bart J, additional, and Heijmans, Jarom, additional

Published
2022
Full Text
View/download PDF

45. Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy and rationale for surveillance- culture-guided empirical therapy; results from an 11-year multi-centre retrospective study

Author

Court, Jara R. de la, primary, Woudt, Sjoukje H. S., additional, Schoffelen, Annelot F., additional, Heijmans, Jarom, additional, de Jonge, Nick A., additional, Bruggen, Tjomme van der, additional, Bomers, Marije K., additional, Lambregts, Merel M. C., additional, Schade, Rogier P., additional, and Sigaloff, Kim C.E., additional

Published
2022
Full Text
View/download PDF

46. Loss of Indian Hedgehog Activates Multiple Aspects of a Wound Healing Response in the Mouse Intestine

Author

van Dop, Willemijn A., Heijmans, Jarom, Büller, Nikè V.J.A., Snoek, Susanne A., Rosekrans, Sanne L., Wassenberg, Elisabeth A., van den Bergh Weerman, Marius A., Lanske, Beate, Clarke, Alan R., Winton, Douglas J., Wijgerde, Mark, Offerhaus, G. Johan, Hommes, Daan W., Hardwick, James C., de Jonge, Wouter J., Biemond, Izak, and van den Brink, Gijs R.

Published
2010
Full Text
View/download PDF

50. Lymfadenopathie in de eerste lijn: Artikel voor onderwijs en opleiding

Author

Heijmans, Jarom, Krausz, Sarah, van Es, Judy M., Kuijpers, Taco W., de Bree, Godelieve J., General Internal Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, General practice, Amsterdam Public Health, Landsteiner Laboratory, Paediatric Infectious Diseases / Rheumatology / Immunology, Amsterdam Reproduction & Development (AR&D), Infectious diseases, APH - Aging & Later Life, and APH - Global Health

Subjects
food and beverages
Abstract

Lymphadenopathy (painfull or enlarged lymph nodes) is a common reason for consulting a physician working in primary or secondary health care. Lymphadenopathy can be the reason for consultation, but can also be observed in patients who present with other complaints. The differential diagnosis is very broad and varies from self-limiting benign disorders, where a wait-and-see policy is sufficient, to a more serious and life-threatening disease for which no further delay is warranted. In daily practice it can sometimes be challenging to determine which policy is indicated. In this article, we propose tools in order to assist the primary care physician to determine which policy is needed in patients presenting with lymphadenopathy.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results